Tag: Neovasc

Neovasc Announces Closing of Final Convertible Debt Issuance for Gross Proceeds of US$5.0 Million

VANCOUVER and MINNEAPOLIS, MN, June 04, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, announced today that, further to its press release dated […]

Neovasc Reducer Spotlighted in Leading German Public Television Program

Elective Interventional Procedures Resume in Germany VANCOUVER and MINNEAPOLIS, MN, June 03, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today announced […]

Neovasc Announces Offering of Convertible Debt and Warrants for Gross Proceeds of up to US$5.0 Million, Warrant Exchange Transaction and Repayment of 2017 Convertible Notes and Related Settlement

VANCOUVER and MINNEAPOLIS, May 26, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, announced today 1) an offering (“Offering”) of convertible notes […]

Neovasc Has Filed for CE Mark for Tiara TA Transapical Mitral Valve Replacement System

Less invasive approach provides hope for the millions of patients that suffer from leaky mitral valves VANCOUVER and MINNEAPOLIS, MN, May 27, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive […]

Neovasc Announces First Quarter Financial Results

Promotes John Panton to Chief Quality Officer VANCOUVER and MINNEAPOLIS, MN, May 07, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today reported […]

Neovasc Will Request Nasdaq Hearing After Company Received Expected Delisting Determination From Nasdaq Staff

VANCOUVER and MINNEAPOLIS, Feb. 20, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that it will […]

Neovasc Achieves Design Freeze for Transfemoral Trans-septal Tiara™ Mitral Valve System

VANCOUVER and MINNEAPOLIS, Feb. 12, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE —Neovasc Inc.. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today achievement of design […]

Neovasc Initiates Independent Inquiry Into Trading of its Shares

Vancouver, Feb. 11, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Company has […]

Neovasc Inc. Investor Update

VANCOUVER, Jan. 13, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, seeks to provide an update for investors, including […]

Neovasc Announces Renewal of German Reimbursement NUB Status 1 Designation for Neovasc Reducer for Treatment of Refractory Angina

VANCOUVER, Jan. 31, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the Institut für […]